Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Health Affairs (Project Hope)|August 2, 2021
Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent LitigationVictor L Van de Wiele, Aaron S Kesselheim, Ameet SarpatwariHealth Affairs (Project Hope)|August 1, 2022
Characteristics Of Key Patents Covering Recent FDA-Approved DrugsVictor L Van de Wiele, Andrew W Torrance, Aaron S KesselheimHealth Affairs (Project Hope)|October 6, 2025
Impact Of Risk Evaluation And Mitigation Strategies On Generic Approvals Of US Pharmaceutical ProductsJennifer Kao, Victor L Van de Wiele, Reed F Beall, et al.The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|May 25, 2023
Transferable Exclusivity Vouchers and Incentives for Antimicrobial Development in the European UnionVictor L Van de Wiele, Adam Raymakers, Aaron S Kesselheim, et al.Health Affairs (Project Hope)|March 3, 2025
Changes In Biologic Drug Revenues After Administrative Patent ChallengesAdam J N Raymakers, Victor L Van de Wiele, Aaron S Kesselheim, et al.Journal of Law and the Biosciences|February 25, 2022
Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseasesVictor L Van de Wiele, Maximilian Hammer, Ravi Parikh, et al.Pharmaceutical Medicine|July 14, 2024
Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USAVictor L Van de Wiele, Aaron S Kesselheim, Deborah Gleeson, et al.JAMA Internal Medicine|September 1, 2020
Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic SubstitutionsChana A Sacks, Victor L Van de Wiele, Lisa A Fulchino, et al.Pageof 1